

Drug Use Research & Management Program DHS - Health Systems Division 500 Summer Street NE, E35, Salem, OR 97301-1079 **Phone** 503-947-5220 | **Fax** 503-947-1119

College of Pharmacy

Pharmacy Utilization Summary Report: October 2021 - September 2022

Eligibility	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthly
Total Members (FFS & Encounter)	1,238,036	1,249,056	1,258,864	1,270,424	1,276,063	1,284,291	1,291,200	1,296,769	1,303,371	1,322,427	1,330,020	1,337,959	1,288,207
FFS Members	111,347	109,132	112,664	117,322	110,548	109,789	112,522	113,945	111,881	115,910	113,720	117,050	112,986
OHP Basic with Medicare	8,429	8,051	8,195	8,488	8,161	8,271	8,510	8,597	8,424	8,606	8,473	8,710	8,410
OHP Basic without Medicare	10,888	10,718	10,697	10,889	10,579	10,500	10,595	10,601	10,503	10,497	10,255	10,368	10,591
ACA	92,030	90,363	93,772	97,945	91,808	91,018	93,417	94,747	92,954	96,807	94,992	97,972	93,985
Encounter Members	1,126,689	1,139,924	1,146,200	1,153,102	1,165,515	1,174,502	1,178,678	1,182,824	1,191,490	1,206,517	1,216,300	1,220,909	1,175,221
OHP Basic with Medicare	84,715	86,139	86,570	87,412	88,084	89,468	90,661	92,068	93,206	94,346	95,446	96,256	90,364
OHP Basic without Medicare	67,983	68,260	68,173	68,310	68,509	68,469	68,580	68,801	68,956	69,022	69,064	68,981	68,592
ACA	973,991	985,525	991,457	997,380	1,008,922	1,016,565	1,019,437	1,021,955	1,029,328	1,043,149	1,051,790	1,055,672	1,016,264

Gross Cost Figures for Drugs	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	YTD Sum
Total Amount Paid (FFS & Encounter)	\$97,567,578	\$100,732,317	\$103,179,492	\$102,652,803	\$98,866,801	\$116,037,955	\$106,332,953	\$111,467,467	\$113,308,637	\$103,993,292	\$116,906,068	\$108,490,863	\$1,279,536,227
Mental Health Carve-Out Drugs	\$10,846,532	\$11,004,341	\$11,202,431	\$11,267,660	\$10,867,921	\$12,312,593	\$11,634,392	\$12,131,859	\$11,933,923	\$11,110,104	\$11,893,706	\$11,165,717	\$137,371,178
OHP Basic with Medicare	\$8,509	\$5,705	\$2,848	\$317	\$11,314	\$7,893	\$11,471	\$9,259	\$10,001	\$7,612	\$3,774	\$5,976	\$84,680
OHP Basic without Medicare	\$4,006,902	\$4,051,571	\$4,176,428	\$4,088,497	\$3,906,186	\$4,429,201	\$4,145,072	\$4,340,706	\$4,414,283	\$3,994,456	\$4,334,167	\$4,142,537	\$50,030,006
ACA	\$6,749,467	\$6,864,294	\$6,935,596	\$7,086,443	\$6,860,346	\$7,776,734	\$7,390,154	\$7,688,337	\$7,431,446	\$7,027,703	\$7,486,978	\$6,954,568	\$86,252,065
FFS Physical Health Drugs	\$4,524,991	\$4,487,916	\$4,568,492	\$4,987,642	\$4,506,737	\$5,042,762	\$5,259,902	\$5,495,477	\$5,205,948	\$4,808,861	\$5,617,932	\$5,107,190	\$59,613,851
OHP Basic with Medicare	\$165,578	\$171,115	\$158,438	\$187,735	\$177,974	\$206,926	\$200,388	\$210,055	\$235,238	\$209,713	\$229,485	\$197,390	\$2,350,037
OHP Basic without Medicare	\$1,201,423	\$1,027,543	\$1,116,720	\$1,132,247	\$989,978	\$1,095,318	\$1,162,627	\$1,223,287	\$1,192,739	\$972,746	\$1,218,045	\$1,021,595	\$13,354,269
ACA	\$3,001,864	\$3,125,176	\$3,193,302	\$3,519,646	\$3,227,953	\$3,624,956	\$3,742,407	\$3,910,375	\$3,647,763	\$3,473,499	\$3,997,429	\$3,735,689	\$42,200,060
FFS Physician Administered Drugs	\$1,435,900	\$1,224,169	\$1,074,441	\$1,248,804	\$1,674,370	\$1,813,360	\$1,366,563	\$1,307,144	\$1,650,727	\$1,299,422	\$1,151,861	\$1,396,051	\$16,642,813
OHP Basic with Medicare	\$59,510	\$153,016	\$155,675	\$165,886	\$150,142	\$142,481	\$146,552	\$103,159	\$110,939	\$180,889	\$138,569	\$163,587	\$1,670,406
OHP Basic without Medicare	\$584,257	\$413,340	\$232,799	\$198,491	\$523,118	\$497,954	\$258,208	\$319,442	\$565,692	\$301,843	\$103,641	\$512,073	\$4,510,858
ACA	\$430,148	\$364,983	\$425,042	\$402,708	\$541,945	\$614,379	\$550,725	\$519,456	\$541,257	\$389,835	\$479,964	\$384,359	\$5,644,799
Encounter Physical Health Drugs	\$63,546,085	\$66,086,120	\$68,053,611	\$67,347,957	\$64,528,143	\$73,979,547	\$69,198,239	\$72,410,288	\$71,999,713	\$67,163,054	\$75,697,235	\$70,769,201	\$830,779,193
OHP Basic with Medicare	\$400,146	\$447,118	\$473,861	\$427,250	\$393,401	\$443,092	\$410,107	\$426,618	\$397,294	\$356,217	\$412,953	\$378,967	\$4,967,023
OHP Basic without Medicare	\$15,462,625	\$16,315,294	\$16,372,701	\$16,514,178	\$16,148,892	\$17,631,263	\$17,063,434	\$17,075,179	\$17,299,326	\$16,374,218	\$17,927,063	\$16,774,895	\$200,959,068
ACA	\$46,928,061	\$48,565,122	\$50,314,400	\$49,541,281	\$47,135,788	\$54,872,117	\$50,690,051	\$53,876,306	\$53,231,767	\$49,220,947	\$55,790,657	\$52,006,452	\$612,172,950
Encounter Physician Administered Drugs	\$17,214,070	\$17,929,770	\$18,280,517	\$17,800,741	\$17,289,631	\$22,889,692	\$18,873,858	\$20,122,698	\$22,518,326	\$19,611,851	\$22,545,334	\$20,052,704	\$235,129,192
OHP Basic with Medicare	\$1,037,778	\$980,990	\$905,449	\$1,087,438	\$880,280	\$1,100,484	\$970,582	\$996,109	\$1,164,351	\$1,120,494	\$1,023,117	\$900,498	\$12,167,570
OHP Basic without Medicare	\$3,845,012	\$4,267,556	\$4,367,050	\$3,854,782	\$4,098,188	\$5,600,190	\$4,456,790	\$5,749,556	\$4,838,108	\$4,529,706	\$5,111,378	\$4,315,757	\$55,034,072
ACA	\$12,159,419	\$12,405,770	\$12,803,305	\$12,603,923	\$12,049,321	\$15,963,650	\$13,277,830	\$13,195,230	\$16,163,987	\$13,695,463	\$16,052,192	\$14,482,603	\$164,852,692

OHP = Oregon Health Plan

ACA = Affordable Care Act expansion

Amount Paid on the Claim = 1) Ingredient Cost ([AAAC/NADAC/WAC] x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount


Last Updated: April 20, 2023




College of Pharmacy

Pharmacy Utilization Summary Report: October 2021 - September 2022

YTD Percent Paid Amounts





OHP = Oregon Health Plan

ACA = Affordable Care Act expansion

PAD = Physician-administered drugs

Amount Paid on the Claim = 1) Ingredient Cost ([AAAC/NADAC/WAC] x Dispense Quantity) + Dispensing Fee.

If Billed Amount is lower, pay Billed Amount, 2) - TPL amount



Drug Use Research & Management Program

DHS - Health Systems Division 500 Summer Street NE, E35, Salem, OR 97301-1079


Phone 503-947-5220 | Fax 503-947-1119

College of Pharmacy

Pharmacy Utilization Summary Report: October 2021 - September 2022

Quarterly Rebates Invoiced	2021-Q4	2022-Q1	2022-Q2	2022-Q3	YTD Sum
Total Rebate Invoiced (FFS & Encounter)	\$112,969,459	\$120,549,011	\$122,909,282	\$153,620,091	\$510,047,842
CMS MH Carve-out	\$17,620,385	\$17,110,132	\$18,172,702	\$16,653,224	\$69,556,443
SR MH Carve-out	\$1,795,141	\$1,341,151	\$1,717,026	\$2,206,833	\$7,060,151
CMS FFS Drug	\$4,764,214	\$4,805,957	\$4,588,856	\$5,343,007	\$19,502,034
SR FFS	\$553,362	\$506,401	\$511,077	\$556,102	\$2,126,942
CMS Encounter	\$79,408,414	\$88,415,263	\$88,806,437	\$118,006,598	\$374,636,712
SR Encounter	\$8,827,942	\$8,370,109	\$9,113,183	\$10,854,326	\$37,165,560

Quaterly Net Drug Costs	2021-Q4	2022-Q1	2022-Q2	2022-Q3	YTD Sum
Estimated Net Drug Costs (FFS & Encounter)	\$188,509,928	\$197,008,548	\$208,199,776	\$175,770,133	\$769,488,385
Mental Health Carve-Out Drugs	\$13,637,777	\$15,996,891	\$15,810,446	\$15,309,469	\$60,754,584
FFS Phys Health + PAD	\$11,998,334	\$13,961,317	\$15,185,828	\$13,482,208	\$54,627,688
Encounter Phys Health + PAD	\$162,873,817	\$167,050,340	\$177,203,502	\$146,978,456	\$654,106,114



SR = Supplemental Rebate

CMS = Center for Medicaid Services

PAD = Physician-administered drugs

MH = Mental Health



College of Pharmacy

Pharmacy Utilization Summary Report: October 2021 - September 2022

Gross PMPM Drug Costs (Rebates not Subtracted)	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthl
PMPM Amount Paid (FFS & Encounter)	\$78.81	\$80.65	\$81.96	\$80.80	\$77.48	\$90.35	\$82.35	\$85.96	\$86.94	\$78.64	\$87.90	\$81.09	\$82.7
Mental Health Carve-Out Drugs	\$8.76	\$8.81	\$8.90	\$8.87	\$8.52	\$9.59	\$9.01	\$9.36	\$9.16	\$8.40	\$8.94	\$8.35	\$8.8
FFS Physical Health Drugs	\$40.64	\$41.12	\$40.55	\$42.51	\$40.77	\$45.93	\$46.75	\$48.23	\$46.53	\$41.49	\$49.40	\$43.63	\$43.96
FFS Physician Administered Drugs	\$12.90	\$11.22	\$9.54	\$10.64	\$15.15	\$16.52	\$12.14	\$11.47	\$14.75	\$11.21	\$10.13	\$11.93	\$12.30
Encounter Physical Health Drugs	\$56.40	\$57.97	\$59.37	\$58.41	\$55.36	\$62.99	\$58.71	\$61.22	\$60.43	\$55.67	\$62.24	\$57.96	\$58.89
Encounter Physician Administered Drugs	\$15.28	\$15.73	\$15.95	\$15.44	\$14.83	\$19.49	\$16.01	\$17.01	\$18.90	\$16.25	\$18.54	\$16.42	\$16.65
Claim Counts	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthly
Total Claim Count (FFS & Encounter)	1,096,840	1,097,603	1,110,758	1,125,464	1,050,206	1,201,373	1,147,555	1,182,939	1,174,102	1,105,437	1,201,473	1,139,812	1,136,130
Mental Health Carve-Out Drugs	183,238	185,502	188,476	190,963	179,890	204,411	193,148	199,466	197,731	189,762	206,390	194,299	192,773
FFS Physical Health Drugs	35,415	35,164	35,897	38,026	34,927	38,390	36,484	37,556	36,602	34,753	36,858	34,797	36,239
FFS Physician Administered Drugs	9,492	8,939	9,243	10,802	9,813	11,629	10,230	10,278	10,107	9,723	9,922	9,346	9,960
Encounter Physical Health Drugs	751,438	751,113	765,430	773,068	717,801	819,815	787,332	813,568	810,933	758,100	828,621	786,713	780,328
Encounter Physician Administered Drugs	117,257	116,885	111,712	112,605	107,775	127,128	120,361	122,071	118,729	113,099	119,682	114,657	116,830
Gross Amount Paid per Claim (Rebates not Subtracted)	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthly
Average Paid / Claim (FFS & Encounter)	\$88.95	\$91.77	\$92.89	\$91.21	\$94.14	\$96.59	\$92.66	\$94.23	\$96.51	\$94.07	\$97.30	\$95.18	\$93.79
Mental Health Carve-Out Drugs	\$59.19	\$59.32	\$59.44	\$59.00	\$60.41	\$60.23	\$60.24	\$60.82	\$60.35	\$58.55	\$57.63	\$57.47	\$59.39
FFS Physical Health Drugs	\$127.77	\$127.63	\$127.27	\$131.16	\$129.03	\$131.36	\$144.17	\$146.33	\$142.23	\$138.37	\$152.42	\$146.77	\$137.04
FFS Physician Administered Drugs	\$151.27	\$136.95	\$116.24	\$115.61	\$170.63	\$155.93	\$133.58	\$127.18	\$163.33	\$133.64	\$116.09	\$149.37	\$139.15
Encounter Physical Health Drugs	\$84.57	\$87.98	\$88.91	\$87.12	\$89.90	\$90.24	\$87.89	\$89.00	\$88.79	\$88.59	\$91.35	\$89.96	\$88.69
Encounter Physician Administered Drugs	\$146.81	\$153.40	\$163.64	\$158.08	\$160.42	\$180.05	\$156.81	\$164.84	\$189.66	\$173.40	\$188.38	\$174.89	\$167.53
,		·			•	•		-	-	·			
Gross Amount Paid per Claim - Generic-Multi Source Drugs (Rebates not Subtracted)	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthly
Generic-Multi Source Drugs: Average Paid / Claim (FFS & Encounter)	\$22.01	\$22.59	\$22.84	\$23.10	\$23.25	\$23.57	\$24.00	\$24.02	\$24.49	\$24.44	\$24.99	\$25.02	\$23.69
Mental Health Carve-Out Drugs	\$16.23	\$16.44	\$16.35	\$16.49	\$16.42	\$16.30	\$16.64	\$16.82	\$17.06	\$17.22	\$17.57	\$17.30	\$16.74
FFS Physical Health Drugs	\$78.01	\$81.29	\$81.05	\$84.31	\$84.17	\$86.98	\$97.23	\$99.59	\$99.68	\$94.71	\$103.46	\$106.42	\$91.41
Encounter Physical Health Drugs	\$21.14	\$21.80	\$22.21	\$22.25	\$22.39	\$22.75	\$22.77	\$22.66	\$23.28	\$23.41	\$23.73	\$23.74	\$22.68
Gross Amount Paid per Claim - Branded-Single Source Drugs (Rebates not Subtracted)	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthly
Branded-Single Source Drugs: Average Paid / Claim (FFS & Encounter)	\$517.43	\$547.40	\$535.48	\$538.46	\$607.04	\$648.11	\$641.20	\$654.25	\$665.94	\$670.46	\$697.81	\$643.94	\$613.96
Mental Health Carve-Out Drugs	\$964.54	\$931.86	\$950.74	\$946.47	\$965.71	\$963.43	\$962.47	\$964.43	\$1,020.82	\$1,085.82	\$1,115.90	\$1,146.87	\$1,001.59
FFS Physical Health Drugs	\$319.51	\$290.46	\$272.83	\$281.82	\$315.12	\$345.82	\$372.77	\$375.53	\$350.00	\$348.94	\$400.59	\$337.85	\$334.27
Encounter Physical Health Drugs	\$494.89	\$533.62	\$522.38	\$525.94	\$595.11	\$637.00	\$627.15	\$641.63	\$653.36	\$656.00	\$682.05	\$625.26	\$599.53
Encounter i hysical reach stags	\$151.05	Ų333.02	\$322.30	Ų323.3 ·	Ų333.11	\$657.66	Ç027.13	Ç011.03	Ç033.30	Ç030.00	Ç002.03	Ç025.20	Ç333.33
Generic Drug Use Percentage	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthly
Generic Drug Use Percentage	88.0%	88.3%	87.9%	88.3%	89.3%	90.0%	90.2%	90.2%	90.5%	90.7%	90.8%	90.2%	89.5%
Mental Health Carve-Out Drugs	95.5%	95.3%	95.4%	95.4%	95.4%	95.4%	95.4%	95.4%	95.7%	96.1%	96.4%	96.4%	95.6%
FFS Physical Health Drugs	79.4%	77.8%	75.9%	76.3%	80.6%	82.9%	83.0%	83.1%	83.0%	82.8%	83.5%	82.6%	80.9%
Encounter Physical Health Drugs	86.6%	87.1%	86.7%	87.1%	88.2%	89.0%	89.2%	89.3%	89.6%	89.7%	89.7%	89.0%	88.4%
Preferred Drug Use Percentage	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Avg Monthly
Preferred Drug Use Percentage	89.88%	89.82%	89.76%	89.84%	89.81%	89.89%	89.88%	89.89%	89.82%	90.49%	90.42%	90.45%	90.0%
Mental Health Carve-Out Drugs	93.47%	93.34%	93.35%	93.31%	93,29%	93,31%	93.33%	93.31%	93,27%	93.24%	93.13%	93.13%	93.3%
FFS Physical Health Drugs	94.80%	94.96%	94.98%	94.52%	94.43%	94.54%	94.65%	94.80%	94.90%	95.65%	95.76%	95.68%	95.0%
Encounter Physical Health Drugs	88.78%	88.73%	88.65%	88.78%	88.73%	88.84%	88.85%	88.86%	88.79%	89.61%	89.54%	89.59%	89.0%
	55570		/0										23.070

Amount Paid on the Claim = 1) Ingredient Cost ([AAAC/NADAC/WAC] x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount

Last Updated: April 20, 2023



Drug Use Research & Management Program

DHS - Health Systems Division
500 Summer Street NE, E35, Salem, OR 97301-1079 **Phone** 503-947-5220 | **Fax** 503-947-1119

College of Pharmacy

Top 40 Drugs by Gross Amount Paid (FFS Only) - First Quarter 2023

TATUDA*				Amount	% Total	Claim	Avg Paid	
NINEGA SUSTENNA	Rank	Drug			FFS Costs	Count	per Claim	
YRAYLAR*	1	LATUDA*	Antipsychotics, 2nd Gen	\$5,310,994	12.0%	4,277		Υ
## REXULTI* Antipsychotics, 2nd Gen	2	INVEGA SUSTENNA	Antipsychotics, Parenteral	\$4,183,668	9.5%	1,742	\$2,402	Υ
5 ABILIFY MAINTENA Antipsychotics, Parenteral \$2,239,350 5.1% 977 \$2,292 Y 6 INVEGA TRINZA Antipsychotics, Parenteral \$990,510 2.2% 136 \$7,283 Y 7 ARISTADA Antipsychotics, Parenteral \$856,384 1.9% 357 \$2,339 Y 8 TRINTELLIX Antidepressants \$850,345 1.9% 1,954 \$435 V 9 SERTRALINE HCL Antidepressants \$595,076 1.3% 425 \$13,94 V 10 CAPLYTA* Antipsychotics, 2nd Gen \$592,347 1.3% 42512 \$13 Y 11 BUPROPION XL Antidepressants \$575,652 1.3% 45,212 \$13 Y 12 DULOXETINE HCL Antidepressants \$512,170 1.2% 45,085 \$11 Y 13 FLUOXETINE HCL Antidepressants \$512,170 1.1% 49,446 \$10 15 Epoetin Beta Eral Use Physican Administered Drug \$497,879 1.1% 60 \$8,298 16 LYBAU!** Antip	3	VRAYLAR*	Antipsychotics, 2nd Gen	\$3,879,219	8.8%	3,208	\$1,209	Υ
Find	4	REXULTI*	Antipsychotics, 2nd Gen	\$2,332,005	5.3%	1,846	\$1,263	V
7 ARISTADA Antigoychotics, Parenteral \$856,384 1.9% 357 \$23,399 Y 8 TRINTELIUX Antidepressants \$850,345 1.9% 1.954 \$4355 V 9 SERTRALINE HCL Antidepressants \$595,070 1.3% 61,129 \$10 Y 10 CAPLYTA* Antidepressants \$595,652 1.3% 45,212 \$13,94 Y 11 BUPROPION XL Antidepressants \$575,652 1.3% 45,212 \$13 Y 12 DULOXETINE HCL Antidepressants \$512,170 1.2% 45,212 \$13 Y 13 FLUOXETINE HCL Antidepressants \$512,170 1.2% 45,085 \$11 Y 14 TRAZODONE HCL Antidepressants \$506,627 1.1% 460 \$8,298 16 LYBALV* Antidepressants \$546,877 1.0% 346 \$1,321 Y 15 Epoetin Beta Esrd Use Physican Administered Drug \$49,709 1.1% 40,383 \$10 Y 16 LYBALV Antidepressants	5	ABILIFY MAINTENA	Antipsychotics, Parenteral	\$2,239,350	5.1%	977	\$2,292	Υ
8 TRINTELLIX Antidepressants \$850,345 1.9% 1.954 \$435 V 9 SERTRALINE HCL Antidepressants \$595,070 1.3% 61,129 \$10 V 10 CAPLYTA* Antipsychotics, 2nd Gen \$592,347 1.3% 425 \$1,394 V 11 BUPROPION XL Antidepressants \$575,652 1.3% 45,212 \$13 Y 13 FLUOXETINE HCL Antidepressants \$512,170 1.2% 45,085 \$11 Y 14 TRAZODONE HCL Antidepressants \$506,627 1.1% 49,446 \$10 15 Epocetin Beta Esrd Use Physican Administered Drug \$497,879 1.1% 60 \$8,298 16 LYBALVI* Antidepressants \$446,874 1.0% 346 \$1,321 V 17 ESCTLADPRAM OXALATE Antidepressants \$446,874 1.0% 44,357 \$10 Y 18 ATOMOXETINE HCL STC 07 - Ataractics, Tranquilizers \$344,838 0.8% 27,775 \$12 LAMOTRIGINE Antiepileptics, Outpatient \$327,3	6	INVEGA TRINZA	Antipsychotics, Parenteral	\$990,510	2.2%	136	\$7,283	Υ
9 SERTRALINE HCL Antidepressants \$595,070 1.3% 61,129 \$10 Y 10 CAPLYTA* Antipsychotics, 2nd Gen \$592,347 1.3% 425 \$1,394 Y 18 UPROPION XI. Antidepressants \$573,652 1.3% 425 \$1,394 Y 12 DULOXETINE HCL Antidepressants \$573,652 1.2% 38,138 \$14 Y 17 RAZODONE HCL Antidepressants \$512,170 1.2% 45,085 \$11 Y 18 TRAZODONE HCL Antidepressants \$512,170 1.2% 45,085 \$11 Y 18 TRAZODONE HCL Antidepressants \$506,627 1.1% 49,446 \$10 P 15 Epoetin Beta Esrd Use Physican Administered Drug \$497,879 1.1% 60 \$8,298 P	7	ARISTADA	Antipsychotics, Parenteral	\$856,384	1.9%	357	\$2,399	Υ
10 CAPLYTA*	8	TRINTELLIX	Antidepressants	\$850,345	1.9%	1,954	\$435	V
BUPROPION XL	9	SERTRALINE HCL	Antidepressants	\$595,070	1.3%	61,129	\$10	Υ
DULOXETINE HCL	10	CAPLYTA*	Antipsychotics, 2nd Gen	\$592,347	1.3%	425	\$1,394	V
FLUOXETINE HCL	11	BUPROPION XL	Antidepressants	\$575,652	1.3%	45,212	\$13	Υ
TRAZODONE HCL	12	DULOXETINE HCL	Antidepressants	\$543,352	1.2%	38,138	\$14	Υ
Epoetin Beta Esrd Use	13	FLUOXETINE HCL	Antidepressants	\$512,170	1.2%	45,085	\$11	Υ
16 LYBALVI* Antipsychotics, 2nd Gen \$457,010 1.0% 346 \$1,321 V 17 ESCITALOPRAM OXALATE Antidepressants \$446,874 1.0% 44,357 \$10 Y 18 ATOMOXETINE HCL* ADHD Drugs \$379,902 0.9% 8,475 \$45 Y 19 BUSPIRONE HCL STC 07 - Ataractics, Tranquilizers \$344,838 0.8% 27,775 \$12 20 LAMOTRIGINE Antiepileptics, Outpatient \$327,389 0.7% 29,906 \$11 Y 21 SPRAVATO* Antidepressants \$321,949 0.7% 250 \$1,288 V 24 Agalsidase Beta Injection Physican Administered Drug \$294,122 0.7% 26 \$11,312 Y 24 RISPERDAL CONSTA* Antipsychotics, Parenteral \$268,056 0.6% 259 \$1,035 Y 25 LAMOTRIGINE ER Antiepileptics, Outpatient \$265,247 0.6% 3,548 \$75 V 26 BIKTARV	14	TRAZODONE HCL	Antidepressants	\$506,627	1.1%	49,446	\$10	
ESCITALOPRAM OXALATE	15	Epoetin Beta Esrd Use	Physican Administered Drug	\$497,879	1.1%	60	\$8,298	
ATOMOXETINE HCL* ADHD Drugs \$379,902 0.9% 8,475 \$45 Y	16	LYBALVI*	Antipsychotics, 2nd Gen	\$457,010	1.0%	346	\$1,321	V
BUSPIRONE HCL STC 07 - Ataractics, Tranquilizers \$344,838 0.8% 27,775 \$12 \$12 \$12 \$12 \$13 \$1	17	ESCITALOPRAM OXALATE	Antidepressants	\$446,874	1.0%	44,357	\$10	Υ
LAMOTRIGINE	18	ATOMOXETINE HCL*	ADHD Drugs	\$379,902	0.9%	8,475	\$45	Υ
SPRAVATO*	19	BUSPIRONE HCL	STC 07 - Ataractics, Tranquilizers	\$344,838	0.8%	27,775	\$12	
22 Agalsidase Beta Injection Physican Administered Drug \$294,122 0.7% 26 \$11,312 23 ARIPIPRAZOLE* Antipsychotics, 2nd Gen \$273,704 0.6% 20,835 \$13 Y 24 RISPERDAL CONSTA* Antipsychotics, Parenteral \$268,056 0.6% 259 \$1,035 Y 25 LAMOTRIGINE ER Antiepileptics, Outpatient \$265,247 0.6% 3,548 \$75 V 26 BIKTARVY HIV \$262,327 0.6% 10.66 \$2,475 Y 27 BUPROPION XL Antidepressants \$244,890 0.6% 1,349 5182 V 28 TRIKAFTA* Cystic Fibrosis \$238,103 0.5% 30 \$7,937 N 29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y 31 Inj, Nusinersen, 0.1mg Physican Administered Drug \$229,054 0.5% 20,876 \$11 Y 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N	20	LAMOTRIGINE	Antiepileptics, Outpatient	\$327,389	0.7%	29,906	\$11	Υ
ARIPIPRAZOLE* Antipsychotics, 2nd Gen \$273,704 0.6% 20,835 \$13 Y 24 RISPERDAL CONSTA* Antipsychotics, Parenteral \$268,056 0.6% 259 \$1,035 Y 25 LAMOTRIGINE ER Antiepileptics, Outpatient \$265,247 0.6% 3,548 \$75 V 26 BIKTARVY HIV \$262,327 0.6% 106 \$2,475 Y 27 BUPROPION XL Antidepressants \$224,890 0.6% 1,349 \$182 V 28 TRIKAFTA* Cystic Fibrosis \$238,103 0.5% 30 \$7,937 N 29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y 30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$229,054 0.5% 20,876 \$11 Y 31 Inj, Nusinersen, 0.1mg Physican Administered Drug \$227,819 0.5% 1 \$227,819 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAYYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$1373,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y *Purg requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	21	SPRAVATO*	Antidepressants	\$321,949	0.7%	250	\$1,288	V
24 RISPERDAL CONSTA* Antipsychotics, Parenteral \$268,056 0.6% 259 \$1,035 Y 25 LAMOTRIGINE ER Antiepileptics, Outpatient \$265,247 0.6% 3,548 \$75 V 26 BIKTARVY HIV \$262,327 0.6% 106 \$2,475 Y 27 BUPROPION XL Antidepressants \$244,890 0.6% 1,349 \$182 V 28 TRIKAFTA* Cystic Fibrosis \$238,103 0.5% 30 \$7,937 N 29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y 30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$227,819 0.5% 20,876 \$11 Y 31 Inji, Nusinersen, 0.1mg Physican Administered Drug \$227,819 0.5% 20,876 \$11 Y 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA*	22	Agalsidase Beta Injection	Physican Administered Drug	\$294,122	0.7%	26	\$11,312	
25 LAMOTRIGINE ER Antiepileptics, Outpatient \$265,247 0.6% 3,548 \$75 V 26 BIKTARVY HIV \$262,327 0.6% 106 \$2,475 Y 27 BUPROPION XL Antidepressants \$244,890 0.6% 1,349 \$182 V 28 TRIKAFTA* Cystic Fibrosis \$238,103 0.5% 30 \$7,937 N 29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y Y 30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$229,054 0.5% 20,876 \$11 Y Y Y Y Y Y Y Y Y	23	ARIPIPRAZOLE*	Antipsychotics, 2nd Gen	\$273,704	0.6%	20,835	\$13	Υ
25 LAMOTRIGINE ER Antiepileptics, Outpatient \$265,247 0.6% 3,548 \$75 V 26 BIKTARVY HIV \$262,327 0.6% 106 \$2,475 Y 27 BUPROPION XL Antidepressants \$244,890 0.6% 1,349 \$182 V 28 TRIKAFTA* Cystic Fibrosis \$238,103 0.5% 30 \$7,937 N 29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y Y 30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$229,054 0.5% 20,876 \$11 Y Y Y Y Y Y Y Y Y	24	RISPERDAL CONSTA*	Antipsychotics, Parenteral	\$268,056	0.6%	259	\$1,035	Υ
27 BUPROPION XL Antidepressants \$244,890 0.6% 1,349 \$182 V 28 TRIKAFTA* Cystic Fibrosis \$238,103 0.5% 30 \$7,937 N 29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y 30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$229,054 0.5% 20,876 \$11 Y 31 Inj, Nusinersen, 0.1mg Physican Administered Drug \$227,819 0.5% 1 \$227,819 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y	25	LAMOTRIGINE ER	Antiepileptics, Outpatient	\$265,247	0.6%	3,548	\$75	V
28 TRIKAFTA* Cystic Fibrosis \$238,103 0.5% 30 \$7,937 N 29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y 30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$229,054 0.5% 20,876 \$11 Y 31 Inj, Nusinersen, 0.1mg Physican Administered Drug \$227,819 0.5% 1 \$227,819 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 38 PALIPERIDONE ER* An	26	BIKTARVY	HIV	\$262,327	0.6%	106	\$2,475	Υ
29 VENLAFAXINE HCL ER Antidepressants \$237,133 0.5% 19,173 \$12 Y 30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$229,054 0.5% 20,876 \$11 Y 31 Inj, Nusinersen, 0.1mg Physican Administered Drug \$227,819 0.5% 1 \$227,819 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$170,510 0.4% 1,702 \$102 V 39 OLANZAPINE* Antidepressants \$169,999 0.4% 14,331 <t< td=""><td>27</td><td>BUPROPION XL</td><td>Antidepressants</td><td>\$244,890</td><td>0.6%</td><td>1,349</td><td>\$182</td><td>V</td></t<>	27	BUPROPION XL	Antidepressants	\$244,890	0.6%	1,349	\$182	V
30 QUETIAPINE FUMARATE* Antipsychotics, 2nd Gen \$229,054 0.5% 20,876 \$11 Y 31 Inj, Nusinersen, 0.1mg Physican Administered Drug \$227,819 0.5% 1 \$227,819 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$170,510 0.4% 1,702 \$102 V 39 OLANZAPINE* <t< td=""><td>28</td><td>TRIKAFTA*</td><td>Cystic Fibrosis</td><td>\$238,103</td><td>0.5%</td><td>30</td><td>\$7,937</td><td>N</td></t<>	28	TRIKAFTA*	Cystic Fibrosis	\$238,103	0.5%	30	\$7,937	N
31 Inj, Nusinersen, 0.1mg Physican Administered Drug \$227,819 0.5% 1 \$227,819 32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y	29	VENLAFAXINE HCL ER	Antidepressants	\$237,133	0.5%	19,173	\$12	Υ
32 STELARA* Targeted Immune Modulators \$216,090 0.5% 31 \$6,971 N 33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y *Drug requires Prior Authorization *Drug r	30	QUETIAPINE FUMARATE*	Antipsychotics, 2nd Gen	\$229,054	0.5%	20,876	\$11	Υ
33 CONCERTA* ADHD Drugs \$211,398 0.5% 595 \$355 Y 34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y * Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	31	Inj, Nusinersen, 0.1mg	Physican Administered Drug	\$227,819	0.5%	1	\$227,819	
34 Elosulfase Alfa, Injection Physican Administered Drug \$204,883 0.5% 12 \$17,074 35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y *Drug requires Prior Authorization **Top 40 Aggregate: **Top 40 Aggregate: **30,962,171 494,383 \$7,922	32	STELARA*	Targeted Immune Modulators	\$216,090	0.5%	31	\$6,971	N
35 CITALOPRAM HBR Antidepressants \$180,225 0.4% 20,422 \$9 Y 36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y * Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	33	CONCERTA*	ADHD Drugs	\$211,398	0.5%	595	\$355	Υ
36 MAVYRET* Hepatitis C, Direct-Acting Antivirals \$178,680 0.4% 17 \$10,511 Y 37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y * Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	34	Elosulfase Alfa, Injection	Physican Administered Drug	\$204,883	0.5%	12	\$17,074	
37 MIRTAZAPINE Antidepressants \$173,291 0.4% 12,571 \$14 Y 38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y * Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	35	CITALOPRAM HBR	Antidepressants	\$180,225	0.4%	20,422	\$9	Υ
38 PALIPERIDONE ER* Antipsychotics, 2nd Gen \$173,105 0.4% 1,702 \$102 V 39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y * Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	36	MAVYRET*	Hepatitis C, Direct-Acting Antivirals	\$178,680	0.4%	17	\$10,511	Υ
39 OLANZAPINE* Antipsychotics, 2nd Gen \$170,510 0.4% 13,398 \$13 Y 40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y * Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	37	MIRTAZAPINE	Antidepressants	\$173,291	0.4%	12,571	\$14	Υ
40 AMITRIPTYLINE HCL* Antidepressants \$169,999 0.4% 14,331 \$12 Y * Drug requires Prior Authorization *Top 40 Aggregate: \$30,962,171 494,383 \$7,922	38	PALIPERIDONE ER*	Antipsychotics, 2nd Gen	\$173,105	0.4%	1,702	\$102	V
* Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	39	OLANZAPINE*	Antipsychotics, 2nd Gen	\$170,510	0.4%	13,398	\$13	Υ
* Drug requires Prior Authorization Top 40 Aggregate: \$30,962,171 494,383 \$7,922	40	AMITRIPTYLINE HCL*	Antidepressants	\$169,999	0.4%	14,331	\$12	Υ
All FFS Drugs Totals: \$44,189,202 743,730 \$730	* -	an anning a Daise Anatherina	Top 40 Aggregate:	\$30,962,171		494,383	\$7,922	
	→ Drug	requires Prior Authorization	All FFS Drugs Totals:	\$44,189,202		743,730	\$730	

Notes

⁻ FFS Drug Gross Costs only, rebates not subtracted

⁻ PDL Key: Y=Preferred, N=Non-Preferred, V=Voluntary, Blank=Non PDL Class

⁻ Amount Paid on the Claim = 1) Ingredient Cost ([AAAC/NADAC/WAC] x Dispense Quantity) + Dispensing Fee. If Billed Amount is lower, pay Billed Amount, 2) - TPL amount



Drug Use Research & Management Program

DHS - Health Systems Division
500 Summer Street NE, E35, Salem, OR 97301-1079 **Phone** 503-947-5220 | **Fax** 503-947-1119

College of Pharmacy

Top 40 Physical Health Drugs by Gross Amount Paid (FFS Only) - First Quarter 2023

Rank	Drug	PDL Class	Amount Paid	% Total FFS Costs	Claim Count	Avg Paid per Claim	PDL
1	Epoetin Beta Esrd Use	Physican Administered Drug	\$497,879	4.4%	60	\$8,298	
2	Agalsidase Beta Injection	Physican Administered Drug	\$294,122	2.6%	26	\$11,312	
3	BIKTARVY	HIV	\$262,327	2.3%	106	\$2,475	Υ
4	TRIKAFTA*	Cystic Fibrosis	\$238,103	2.1%	30	\$7,937	N
5	Inj, Nusinersen, 0.1mg	Physican Administered Drug	\$227,819	2.0%	1	\$227,819	
6	STELARA*	Targeted Immune Modulators	\$216,090	1.9%	31	\$6,971	N
7	CONCERTA*	ADHD Drugs	\$211,398	1.9%	595	\$355	Y
8	Elosulfase Alfa, Injection	Physican Administered Drug	\$204,883	1.8%	12	\$17,074	
9	MAVYRET*	Hepatitis C, Direct-Acting Antivirals	\$178,680	1.6%	17	\$10,511	Υ
10	VYVANSE*	ADHD Drugs	\$168,585	1.5%	910	\$185	Y
11	Iron Sucrose Injection	Physican Administered Drug	\$143,984	1.3%	446	\$323	
12	Inj., Emicizumab-Kxwh 0.5 Mg	Physican Administered Drug	\$139,422	1.2%	3	\$46,474	
13	LANTUS SOLOSTAR*	Diabetes, Insulins	\$137,760	1.2%	440	\$313	Υ
14	IBRANCE*	Antineoplastics, Newer	\$135,801	1.2%	9	\$15,089	
15	HUMIRA(CF) PEN*	Targeted Immune Modulators	\$132,941	1.2%	63	\$2,110	Υ
16	COSENTYX PEN (2 PENS)*	Targeted Immune Modulators	\$126,581	1.1%	30	\$4,219	Υ
17	ELIQUIS	Anticoagulants, Oral and SQ	\$118,755	1.1%	325	\$365	Υ
18	TRULICITY*	Diabetes, GLP-1 Receptor Agonistse and GIP the	\$118,012	1.1%	231	\$511	Υ
19	EPIDIOLEX*	Antiepileptics, Outpatient	\$116,286	1.0%	109	\$1,067	N
20	Etonogestrel Implant System	Physican Administered Drug	\$112,861	1.0%	165	\$684	
21	SABRIL	Antiepileptics, Outpatient	\$100,261	0.9%	3	\$33,420	N
22	CHOLBAM*	Bile Therapy	\$99,610	0.9%	1	\$99,610	N
23	SPRYCEL	STC 30 - Antineoplastic	\$99,609	0.9%	11	\$9,055	
24	SUBLOCADE	Substance Use Disorders, Opioid & Alcohol	\$98,830	0.9%	55	\$1,797	Υ
25	Inj Pembrolizumab	Physican Administered Drug	\$92,977	0.8%	36	\$2,583	
26	Aflibercept Injection	Physican Administered Drug	\$92,747	0.8%	174	\$533	
27	Injection, Ocrelizumab, 1 Mg	Physican Administered Drug	\$89,307	0.8%	6	\$14,884	
28	ALBUTEROL SULFATE HFA	Beta-Agonists, Inhaled Short-Acting	\$89,142	0.8%	2,908	\$31	Υ
29	CREON	Pancreatic Enzymes	\$87,591	0.8%	73	\$1,200	Υ
30	BUPRENORPHINE-NALOXONE*	Substance Use Disorders, Opioid & Alcohol	\$81,840	0.7%	1,327	\$62	Υ
31	Mirena, 52 Mg	Physican Administered Drug	\$79,364	0.7%	120	\$661	
32	VERZENIO*	Antineoplastics, Newer	\$77,483	0.7%	8	\$9,685	
33	KESIMPTA PEN*	Multiple Sclerosis	\$73,465	0.7%	3	\$24,488	N
34	Epoetin Alfa, 100 Units Esrd	Physican Administered Drug	\$72,084	0.6%	616	\$117	
35	METYROSINE	STC 71 - Other Hypotensives	\$69,850	0.6%	3	\$23,283	
36	OZEMPIC*	Diabetes, GLP-1 Receptor Agonistse and GIP the	\$65,526	0.6%	165	\$397	N
37	PULMOZYME	Cystic Fibrosis	\$61,877	0.6%	49	\$1,263	Υ
38	HUMIRA(CF)*	Targeted Immune Modulators	\$61,760	0.6%	18	\$3,431	Υ
39	Injection, Nivolumab	Physican Administered Drug	\$61,415	0.5%	15	\$4,094	
40	LENALIDOMIDE	STC 30 - Antineoplastic	\$60,501	0.5%	3	\$20,167	
		Top 40 Aggregate:	\$5,397,527		9,203	\$15,371	
* Drug	requires Prior Authorization	All FFS Drugs Totals:	\$11,213,991		121,339	\$752	

Notes

⁻ FFS Drug Gross Costs only, rebates not subtracted

⁻ PDL Key: Y=Preferred, N=Non-Preferred, V=Voluntary, Blank=Non PDL Class

⁻ Amount Paid on the Claim = 1) Ingredient Cost ([AAAC/NADAC/WAC] x Dispense Quantity) + Dispensing Fee. If Billed Amount is lo wer, pay Billed Amount, 2) - TPL amount